| Overview |
| bs-3815R-Cy7 |
| presenilin 2/PS-2 Polyclonal Antibody, Cy7 Conjugated |
| WB, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human presenilin 2/PS-2 |
| 51-150/448 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5664 |
| AD 3L; AD 3LP; AD 4; AD 5; AD3L; AD3LP; AD4; AD5; Alzheimer disease 4; Alzheimer disease familial type 4; E5 1; Presenilin2; Presenilin 2; Presenilin 2; PS 2; PS2; PSEN 2; PSNL 2; PSNL2; STM 2; STM2. |
| Alzheimer's disease (AD) patients with an inherited form of the disease carry mutations in the presenilin proteins (PSEN1; PSEN2) or the amyloid precursor protein (APP). These disease-linked mutations result in increased production of the longer form of amyloid-beta (main component of amyloid deposits found in AD brains). Presenilins are postulated to regulate APP processing through their effects on gamma-secretase, an enzyme that cleaves APP. Also, it is thought that the presenilins are involved in the cleavage of the Notch receptor, such that they either directly regulate gamma-secretase activity or themselves are protease enzymes. Two alternative transcripts of PSEN2 have been identified. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz